Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir Onn

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
Cancer Immunology, Immunotherapy : CII|January 23, 2021
Immunotherapy response modeling by ex-vivo organ culture for lung cancerIris Kamer, Elizabeta Bab-Dinitz, Oranit Zadok, et al.
The British Journal of Radiology|June 27, 2025
Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survivalSarit Appel, Lee Wilk, Akram Saad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancerTakeshi Isobe, Amir Onn, Daniel Morgensztern, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical modelsDavid C Christiani, William Pao, James C DeMartini, et al.
Seminars in Oncology|September 13, 2014
Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivoMoshe Giladi, Uri Weinberg, Rosa S Schneiderman, et al.
International Journal of Radiation Oncology, Biology, Physics|February 13, 2007
Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in miceSatoshi Itasaka, Ritsuko Komaki, Roy S Herbst, et al.
Molecular Cancer Therapeutics|October 5, 2007
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of miceWenjuan Wu, Michael S O'Reilly, Robert R Langley, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungElizabeth Dudnik, Samuel Kareff, Mor Moskovitz, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2019
Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective studyJair Bar, Gal Markel, Teodor Gottfried, et al.
Frontiers in Oncology|August 9, 2021
Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy BiomarkersSameh Daher, Yaacov R Lawrence, Elizabeth Dudnik, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
Cancer Immunology, Immunotherapy : CII|January 23, 2021
Immunotherapy response modeling by ex-vivo organ culture for lung cancerIris Kamer, Elizabeta Bab-Dinitz, Oranit Zadok, et al.
The British Journal of Radiology|June 27, 2025
Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survivalSarit Appel, Lee Wilk, Akram Saad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancerTakeshi Isobe, Amir Onn, Daniel Morgensztern, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical modelsDavid C Christiani, William Pao, James C DeMartini, et al.
Seminars in Oncology|September 13, 2014
Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivoMoshe Giladi, Uri Weinberg, Rosa S Schneiderman, et al.
International Journal of Radiation Oncology, Biology, Physics|February 13, 2007
Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in miceSatoshi Itasaka, Ritsuko Komaki, Roy S Herbst, et al.
Molecular Cancer Therapeutics|October 5, 2007
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of miceWenjuan Wu, Michael S O'Reilly, Robert R Langley, et al.
Journal for Immunotherapy of Cancer|February 18, 2021
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lungElizabeth Dudnik, Samuel Kareff, Mor Moskovitz, et al.
European Journal of Cancer (Oxford, England : 1990)|September 14, 2019
Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective studyJair Bar, Gal Markel, Teodor Gottfried, et al.
Frontiers in Oncology|August 9, 2021
Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy BiomarkersSameh Daher, Yaacov R Lawrence, Elizabeth Dudnik, et al.
Pageof 10